Sovaldi NDA Review Marred By Manufacturing Compliance Issues

Faced with the prospects of FDA non-approval of its priority review hepatitis C drug sofosbuvir, Gilead withdrew a foreign API manufacturer and one of its own testing facilities from the NDA late in the review process due to Good Manufacturing Practice violations and data integrity concerns.